INCB000928 (investigational agent for MF-related anemia)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-05-14 — INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders: Trial-early (Phase 1/2 dose-escalation and expansion): INCB000928 being evaluated as monotherapy or in combination with ruxolitinib in MF patients with transfusion-dependent or symptomatic anemia, assessing safety, tolerability, PK/PD, and efficacy — establishes the registrational pathway for this anemia-targeted agent. (novelty: 4)
Open questions
Related
Contributing findings
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
14-may-2026
novelty 4
per-area 4
introduces